CN109195992A - 多特异性结合偶联物、相关的药物组合物及应用 - Google Patents

多特异性结合偶联物、相关的药物组合物及应用 Download PDF

Info

Publication number
CN109195992A
CN109195992A CN201680085024.9A CN201680085024A CN109195992A CN 109195992 A CN109195992 A CN 109195992A CN 201680085024 A CN201680085024 A CN 201680085024A CN 109195992 A CN109195992 A CN 109195992A
Authority
CN
China
Prior art keywords
cancer
cell
receptor
virus
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680085024.9A
Other languages
English (en)
Inventor
于浩洋
李正成
苏静
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Benhealth Biopharmaceutic Shenzhen Co ltd
Original Assignee
Benhealth Biopharmaceutic Shenzhen Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Benhealth Biopharmaceutic Shenzhen Co ltd filed Critical Benhealth Biopharmaceutic Shenzhen Co ltd
Publication of CN109195992A publication Critical patent/CN109195992A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明提供了多特异性结合偶联物、其相关的组合物和用途。所述偶联物包含通过纳米材料偶联的针对两种或更多种不同受体、共受体、抗原或细胞标志物的结合部分，可用于调节免疫应答、治疗或预防如癌症、自身免疫病、病原体感染或炎性疾病等疾病或病症。

Description

PCT国内申请，说明书已公开。

Claims (18)

  1. PCT国内申请，权利要求书已公开。
CN201680085024.9A 2016-04-29 2016-10-13 多特异性结合偶联物、相关的药物组合物及应用 Pending CN109195992A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2016/080749 2016-04-29
CN2016080749 2016-04-29
PCT/CN2016/101984 WO2017185662A1 (zh) 2016-04-29 2016-10-13 多特异性结合偶联物、相关的药物组合物及应用

Publications (1)

Publication Number Publication Date
CN109195992A true CN109195992A (zh) 2019-01-11

Family

ID=60161787

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680085024.9A Pending CN109195992A (zh) 2016-04-29 2016-10-13 多特异性结合偶联物、相关的药物组合物及应用

Country Status (3)

Country Link
EP (2) EP3450460B1 (zh)
CN (1) CN109195992A (zh)
WO (1) WO2017185662A1 (zh)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113125732A (zh) * 2019-12-31 2021-07-16 博阳生物科技（上海）有限公司 一种白介素6的均相检测试剂盒及其应用
CN113125730A (zh) * 2019-12-31 2021-07-16 博阳生物科技（上海）有限公司 一种白介素6的均相检测试剂盒及其应用
CN114047336A (zh) * 2021-12-13 2022-02-15 大连医科大学 一种用于辅助诊断复发性流产的生物标志物及其应用
CN116173237A (zh) * 2023-03-02 2023-05-30 上海臻上医药科技有限公司 药物制剂及其制备方法、和用途

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10501541B2 (en) 2015-01-27 2019-12-10 Lava Therapeutics B.V. Single domain antibodies targeting CD1d
WO2017219974A1 (zh) 2016-06-22 2017-12-28 本康生物制药（深圳）有限公司 用于肿瘤治疗的双特异性抗体和抗体偶联物及其应用
US20190225701A1 (en) * 2016-09-26 2019-07-25 The Brigham And Women's Hospital, Inc. Regulators of b cell-mediated immunosuppression
EP3599250A4 (en) * 2017-01-24 2021-06-09 Benhealth Biopharmaceutic (Shenzhen) Co., Ltd. ANTIBODY CONJUGATE, ASSOCIATED PHARMACEUTICAL COMPOSITION AND APPLICATION
WO2018166527A1 (zh) * 2017-03-17 2018-09-20 本康生物制药（深圳）有限公司 多特异性抗体、抗体偶联物和相关的药物组合物及应用
US12077586B2 (en) 2018-09-19 2024-09-03 LAVA Therapeutics N.V. Bispecific antibodies for use in the treatment of hematological malignancies
US20220185903A1 (en) * 2019-03-04 2022-06-16 Nantong Yichen Biopharma. Co. Ltd. Novel bispecific binding molecule and drug conjugate thereof
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
WO2023079142A2 (en) 2021-11-05 2023-05-11 Targimmune Therapeutics Ag Targeted linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same
WO2024100046A1 (en) 2022-11-07 2024-05-16 Targimmune Therapeutics Ag Targeted linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same
WO2024100044A1 (en) 2022-11-07 2024-05-16 Targimmune Therapeutics Ag Polyplexes of nucleic acids and targeted conjugates comprising polyethyleneimine and polyethylene glycol

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007047609A2 (en) * 2005-10-19 2007-04-26 Center For Molecular Medicine And Immunology INHIBITION OF PLACENTA GROWTH FACTOR (PlGF) MEDICATED METASTASIS AND/OR ANGIOGENESIS
CN104829730A (zh) * 2015-04-14 2015-08-12 苏静 一种能联合免疫细胞增强肿瘤杀伤能力的双特异性抗体及其制备方法和应用
CN105073128A (zh) * 2013-04-03 2015-11-18 Ibc药品公司 用于诱导对疾病的免疫应答的组合疗法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG46445A1 (en) 1990-01-26 1998-02-20 Immunomedics Inc Vaccines against cancer and infectious diseases
SI1853631T1 (sl) * 2005-01-24 2016-04-29 Board Of Regents, The University Of Texas System Fuzijski konstrukti, ki zajemajo regijo FC in se vežejo na fosfatidilserine, ter njihova terapevtska uporaba
EP3332808B1 (en) * 2005-03-03 2020-09-09 Immunomedics Inc. Humanized l243 antibodies
US7910702B2 (en) 2006-07-28 2011-03-22 The Governors Of The University Of Alberta Recombinant antibodies to sclerotinia antigens
EP2337801A4 (en) * 2008-10-06 2012-07-25 Minerva Biotechnologies Corp MUC1 ANTIBODIES *
CN104284680A (zh) * 2011-12-15 2015-01-14 芝加哥大学 使用对受体的亲和力增加的突变型light分子用于癌症治疗的方法和组合物
EP2922874A4 (en) * 2012-11-21 2016-10-19 Wuhan Yzy Biopharma Co Ltd BISPECIFIC ANTIBODIES
WO2017219974A1 (zh) * 2016-06-22 2017-12-28 本康生物制药（深圳）有限公司 用于肿瘤治疗的双特异性抗体和抗体偶联物及其应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007047609A2 (en) * 2005-10-19 2007-04-26 Center For Molecular Medicine And Immunology INHIBITION OF PLACENTA GROWTH FACTOR (PlGF) MEDICATED METASTASIS AND/OR ANGIOGENESIS
CN105073128A (zh) * 2013-04-03 2015-11-18 Ibc药品公司 用于诱导对疾病的免疫应答的组合疗法
CN104829730A (zh) * 2015-04-14 2015-08-12 苏静 一种能联合免疫细胞增强肿瘤杀伤能力的双特异性抗体及其制备方法和应用

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113125732A (zh) * 2019-12-31 2021-07-16 博阳生物科技（上海）有限公司 一种白介素6的均相检测试剂盒及其应用
CN113125730A (zh) * 2019-12-31 2021-07-16 博阳生物科技（上海）有限公司 一种白介素6的均相检测试剂盒及其应用
CN113125730B (zh) * 2019-12-31 2023-07-07 科美博阳诊断技术(上海)有限公司 一种白介素6的均相检测试剂盒及其应用
CN113125732B (zh) * 2019-12-31 2023-08-08 科美博阳诊断技术(上海)有限公司 一种白介素6的均相检测试剂盒及其应用
CN114047336A (zh) * 2021-12-13 2022-02-15 大连医科大学 一种用于辅助诊断复发性流产的生物标志物及其应用
CN116173237A (zh) * 2023-03-02 2023-05-30 上海臻上医药科技有限公司 药物制剂及其制备方法、和用途

Also Published As

Publication number Publication date
EP3450460A4 (en) 2019-12-25
EP4245775A3 (en) 2023-11-15
EP3450460B1 (en) 2023-07-12
WO2017185662A1 (zh) 2017-11-02
EP3450460A1 (en) 2019-03-06
EP4245775A2 (en) 2023-09-20
EP3450460C0 (en) 2023-07-12

Similar Documents

Publication Publication Date Title
CN109195992A (zh) 多特异性结合偶联物、相关的药物组合物及应用
US11000603B2 (en) Multi-specific binding conjugate, related pharmaceutical compositions and use
JP6767029B2 (ja) 疾患に対する免疫反応を誘導するための併用療法
US10669338B2 (en) Anti-PD-1 checkpoint inhibitor antibodies that block binding of PD-L1 to PD-1
US10111954B2 (en) Combination therapy for inducing immune response to disease
US10245321B2 (en) Combination therapy for inducing immune response to disease
US20160361360A1 (en) Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs
WO2018217227A1 (en) Novel anti-pd-1 checkpoint inhibitor antibodies that block binding of pd-l1 to pd-1
CN108601841A (zh) Abcg2抑制剂与sacituzumab govitecan(immu-132)的组合克服表达trop-2的癌中对sn-38的抗性
US20200230236A1 (en) Combination for t-cell immunotherapy and use thereof
EP3066470A2 (en) Humanized anti-ceacam5 antibody and uses thereof
US20240252537A1 (en) Precision molecular adaptor system for car-t immunotherapy
CN105407891A (zh) 具有cl2a接头的抗体-sn-38免疫缀合物
CN110248680A (zh) 使用抗体-药物缀合物沙西妥珠单抗戈维替康(immu-132)的用于转移性尿路上皮癌的疗法
CN109562172A (zh) 抗HLA-DR抗体药物缀合物IMMU-140(hL243-CL2A-SN-38)在HLA-DR阳性癌症中的功效
CN110382550A (zh) 抗体偶联物、相关的药物组合物及应用
WO2017180565A1 (en) Combination therapy with anti-hla-dr antibodies and kinase inhibitors in hematopoietic cancers

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40002217

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20190111

RJ01 Rejection of invention patent application after publication